NxStage Medical (NXTM) Reaches New 52-Week High at $28.80

NxStage Medical, Inc. (NASDAQ:NXTM) shares hit a new 52-week high during mid-day trading on Monday . The company traded as high as $28.80 and last traded at $28.43, with a volume of 5448 shares. The stock had previously closed at $28.55.

A number of research analysts have recently issued reports on NXTM shares. Zacks Investment Research upgraded shares of NxStage Medical from a “sell” rating to a “hold” rating in a research note on Wednesday, October 10th. BidaskClub upgraded shares of NxStage Medical from a “sell” rating to a “hold” rating in a research note on Friday, October 12th. Finally, ValuEngine upgraded shares of NxStage Medical from a “hold” rating to a “buy” rating in a research note on Friday, October 12th.

The company has a market capitalization of $1.87 billion, a PE ratio of -131.36 and a beta of -0.05.

NxStage Medical (NASDAQ:NXTM) last issued its quarterly earnings results on Tuesday, August 7th. The medical device company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. NxStage Medical had a negative net margin of 3.67% and a negative return on equity of 7.02%. The business had revenue of $106.97 million for the quarter, compared to analyst estimates of $105.35 million. As a group, sell-side analysts expect that NxStage Medical, Inc. will post -0.02 earnings per share for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in NXTM. BlackRock Inc. boosted its holdings in NxStage Medical by 10.5% during the second quarter. BlackRock Inc. now owns 5,289,606 shares of the medical device company’s stock worth $147,581,000 after buying an additional 501,922 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new stake in NxStage Medical during the second quarter worth about $11,424,000. LMR Partners LLP purchased a new stake in NxStage Medical during the second quarter worth about $7,438,000. SG Americas Securities LLC boosted its holdings in NxStage Medical by 2,037.2% during the third quarter. SG Americas Securities LLC now owns 275,019 shares of the medical device company’s stock worth $7,670,000 after buying an additional 262,151 shares in the last quarter. Finally, Water Island Capital LLC boosted its holdings in NxStage Medical by 12.6% during the second quarter. Water Island Capital LLC now owns 1,334,420 shares of the medical device company’s stock worth $37,230,000 after buying an additional 149,713 shares in the last quarter. 83.15% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/11/07/nxstage-medical-nxtm-reaches-new-52-week-high-at-28-80.html.

About NxStage Medical (NASDAQ:NXTM)

NxStage Medical, Inc, a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting.

See Also: How to calculate compound interest

Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply